This study was performed to evaluate the improvement in serum lipid profile and inflammatory parameters in female diabetic rabbits after two month treatment with glimepride, bromocriptine and fluoxtein in order to decrease cardiovascular diseases risk related to type 2diaetes mellitus. Twenty five local female rabbits divided equally in to five groups, four groups were diabetes type 2 induced by alloxan 120 mg/kg and nicotinamide 50 mg/kg and the fifth group was control negative (Cv-).The animal were allocated to different treatment regimen ,dosed orally on daily base for two months treatment, as following, T1 (glimepride 0.11mg/kg),T2 (glimepride 0.11+bromocriptine 0.04 mg/kg),T3 (glimepride 0.11+fluoxtein 0.29 mg/kg), control positive group(Cve+) diabetic without treatment and the fifth group was control negative group (Cve-) dosed with distall water. Lipid profile, interleukin-6,C-reactive protein were determined after diabetes induction and at the end of experiment. IL-6 significantly reduced in T2,while C-Reactive Protein non-significantly reduced. All treated groups showed nearly similar total cholesterol level, T1demonstrate the higher level of High Density Lippoprotein -C level . In the same time all treated groups showed non-significant decrease in Low Density Lippoprotein-C, T2 showed superiority in reducing Very Low DennsityLippoprotein-C and triglyceride level over all other diabetic groups In.conclusion ,diabete agonist (Bromocriptine)+glimepride demonstrate the superiority over the combination therapy glimepride +flouxtein and glimepride as monotherapy in improving diabetes type 2 related cardiovascular complications.